Which has higher earnings & valuation, CARL or OMCL?

Omnicell has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Carlsmed $50.51M 8.23 -$29.63M -$1.43 N/A Omnicell $1.18B 1.25 $2.05M $0.84 38.85

Is CARL or OMCL more profitable?

Omnicell has a net margin of 3.13% compared to Carlsmed's net margin of -57.42%. Omnicell's return on equity of 5.66% beat Carlsmed's return on equity. Company Net Margins Return on Equity Return on Assets Carlsmed -57.42% -38.06% -28.96% Omnicell 3.13% 5.66% 3.57%

Does the media favor CARL or OMCL?

In the previous week, Omnicell had 4 more articles in the media than Carlsmed. MarketBeat recorded 9 mentions for Omnicell and 5 mentions for Carlsmed. Omnicell's average media sentiment score of 1.14 beat Carlsmed's score of 0.62 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carlsmed 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omnicell 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KMTS or CARL?

In the previous week, Kestra Medical Technologies had 24 more articles in the media than Carlsmed. MarketBeat recorded 29 mentions for Kestra Medical Technologies and 5 mentions for Carlsmed. Carlsmed's average media sentiment score of 0.62 beat Kestra Medical Technologies' score of 0.04 indicating that Carlsmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kestra Medical Technologies 6 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Carlsmed 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, CNMD or CARL?

CONMED has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CONMED $1.37B 1.02 $47.06M $1.85 25.33 Carlsmed $50.51M 8.23 -$29.63M -$1.43 N/A

Is CNMD or CARL more profitable?

CONMED has a net margin of 4.12% compared to Carlsmed's net margin of -57.42%. CONMED's return on equity of 14.31% beat Carlsmed's return on equity. Company Net Margins Return on Equity Return on Assets CONMED 4.12% 14.31% 6.33% Carlsmed -57.42% -38.06% -28.96%

Does the media refer more to CNMD or CARL?

In the previous week, Carlsmed had 4 more articles in the media than CONMED. MarketBeat recorded 5 mentions for Carlsmed and 1 mentions for CONMED. CONMED's average media sentiment score of 1.34 beat Carlsmed's score of 0.62 indicating that CONMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CONMED 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Carlsmed 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, CARL or ATEC?

Carlsmed has higher earnings, but lower revenue than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Carlsmed $50.51M 8.23 -$29.63M -$1.43 N/A Alphatec $764.16M 2.15 -$143.36M -$0.71 N/A

Is CARL or ATEC more profitable?

Alphatec has a net margin of -13.49% compared to Carlsmed's net margin of -57.42%. Carlsmed's return on equity of -38.06% beat Alphatec's return on equity. Company Net Margins Return on Equity Return on Assets Carlsmed -57.42% -38.06% -28.96% Alphatec -13.49% -6,752.24% -13.88%

Does the media favor CARL or ATEC?

In the previous week, Alphatec had 6 more articles in the media than Carlsmed. MarketBeat recorded 11 mentions for Alphatec and 5 mentions for Carlsmed. Alphatec's average media sentiment score of 1.06 beat Carlsmed's score of 0.62 indicating that Alphatec is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carlsmed 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alphatec 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TNDM or CARL?

In the previous week, Tandem Diabetes Care and Tandem Diabetes Care both had 5 articles in the media. Tandem Diabetes Care's average media sentiment score of 1.56 beat Carlsmed's score of 0.62 indicating that Tandem Diabetes Care is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tandem Diabetes Care 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Carlsmed 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Carlsmed (CARL) Competitors

$15.23 -0.11 (-0.72%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$15.22 -0.01 (-0.07%)

As of 09/15/2026 04:15 PM Eastern

Compare

CARL vs. OMCL, KMTS, CNMD, ATEC, and TNDM

Should you buy Carlsmed stock or one of its competitors? Carlsmed's main competitors and comparable companies include Omnicell (OMCL), Kestra Medical Technologies (KMTS), CONMED (CNMD), Alphatec (ATEC), and Tandem Diabetes Care (TNDM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Carlsmed compare to Omnicell?

Carlsmed (NASDAQ:CARL) and Omnicell (NASDAQ:OMCL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

97.7% of Omnicell shares are owned by institutional investors. 12.9% of Carlsmed shares are owned by insiders. Comparatively, 2.9% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Carlsmed has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, Omnicell has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Carlsmed presently has a consensus target price of $19.25, suggesting a potential upside of 26.40%. Omnicell has a consensus target price of $57.86, suggesting a potential upside of 77.31%. Given Omnicell's stronger consensus rating and higher possible upside, analysts plainly believe Omnicell is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Omnicell has a net margin of 3.13% compared to Carlsmed's net margin of -57.42%. Omnicell's return on equity of 5.66% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.42%	-38.06%	-28.96%
Omnicell	3.13%	5.66%	3.57%

Omnicell has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	8.23	-$29.63M	-$1.43	N/A
Omnicell	$1.18B	1.25	$2.05M	$0.84	38.85

In the previous week, Omnicell had 4 more articles in the media than Carlsmed. MarketBeat recorded 9 mentions for Omnicell and 5 mentions for Carlsmed. Omnicell's average media sentiment score of 1.14 beat Carlsmed's score of 0.62 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Carlsmed	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Omnicell beats Carlsmed on 13 of the 16 factors compared between the two stocks.

How does Carlsmed compare to Kestra Medical Technologies?

Kestra Medical Technologies (NASDAQ:KMTS) and Carlsmed (NASDAQ:CARL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Carlsmed has a net margin of -57.42% compared to Kestra Medical Technologies' net margin of -140.43%. Carlsmed's return on equity of -38.06% beat Kestra Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kestra Medical Technologies	-140.43%	-62.82%	-45.42%
Carlsmed	-57.42%	-38.06%	-28.96%

In the previous week, Kestra Medical Technologies had 24 more articles in the media than Carlsmed. MarketBeat recorded 29 mentions for Kestra Medical Technologies and 5 mentions for Carlsmed. Carlsmed's average media sentiment score of 0.62 beat Kestra Medical Technologies' score of 0.04 indicating that Carlsmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kestra Medical Technologies	6 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Carlsmed	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kestra Medical Technologies presently has a consensus target price of $28.38, indicating a potential upside of 12.69%. Carlsmed has a consensus target price of $19.25, indicating a potential upside of 26.40%. Given Carlsmed's stronger consensus rating and higher possible upside, analysts plainly believe Carlsmed is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kestra Medical Technologies	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Carlsmed has lower revenue, but higher earnings than Kestra Medical Technologies. Carlsmed is trading at a lower price-to-earnings ratio than Kestra Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kestra Medical Technologies	$95.13M	15.51	-$131.61M	-$2.42	N/A
Carlsmed	$50.51M	8.23	-$29.63M	-$1.43	N/A

Kestra Medical Technologies has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, Carlsmed has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market.

Summary

Carlsmed beats Kestra Medical Technologies on 9 of the 13 factors compared between the two stocks.

How does Carlsmed compare to CONMED?

CONMED (NYSE:CNMD) and Carlsmed (NASDAQ:CARL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

CONMED has a net margin of 4.12% compared to Carlsmed's net margin of -57.42%. CONMED's return on equity of 14.31% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CONMED	4.12%	14.31%	6.33%
Carlsmed	-57.42%	-38.06%	-28.96%

CONMED presently has a consensus price target of $41.40, suggesting a potential downside of 11.67%. Carlsmed has a consensus price target of $19.25, suggesting a potential upside of 26.40%. Given Carlsmed's stronger consensus rating and higher possible upside, analysts plainly believe Carlsmed is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CONMED	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Carlsmed had 4 more articles in the media than CONMED. MarketBeat recorded 5 mentions for Carlsmed and 1 mentions for CONMED. CONMED's average media sentiment score of 1.34 beat Carlsmed's score of 0.62 indicating that CONMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CONMED	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Carlsmed	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CONMED has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Carlsmed has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market.

CONMED has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CONMED	$1.37B	1.02	$47.06M	$1.85	25.33
Carlsmed	$50.51M	8.23	-$29.63M	-$1.43	N/A

Summary

CONMED beats Carlsmed on 8 of the 14 factors compared between the two stocks.

How does Carlsmed compare to Alphatec?

Carlsmed (NASDAQ:CARL) and Alphatec (NASDAQ:ATEC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Carlsmed presently has a consensus target price of $19.25, suggesting a potential upside of 26.40%. Alphatec has a consensus target price of $17.40, suggesting a potential upside of 63.23%. Given Alphatec's stronger consensus rating and higher possible upside, analysts plainly believe Alphatec is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alphatec	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Carlsmed has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market. Comparatively, Alphatec has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Carlsmed has higher earnings, but lower revenue than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	8.23	-$29.63M	-$1.43	N/A
Alphatec	$764.16M	2.15	-$143.36M	-$0.71	N/A

Alphatec has a net margin of -13.49% compared to Carlsmed's net margin of -57.42%. Carlsmed's return on equity of -38.06% beat Alphatec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.42%	-38.06%	-28.96%
Alphatec	-13.49%	-6,752.24%	-13.88%

In the previous week, Alphatec had 6 more articles in the media than Carlsmed. MarketBeat recorded 11 mentions for Alphatec and 5 mentions for Carlsmed. Alphatec's average media sentiment score of 1.06 beat Carlsmed's score of 0.62 indicating that Alphatec is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Carlsmed	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alphatec	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

66.4% of Alphatec shares are owned by institutional investors. 12.9% of Carlsmed shares are owned by insiders. Comparatively, 13.5% of Alphatec shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Alphatec beats Carlsmed on 11 of the 16 factors compared between the two stocks.

How does Carlsmed compare to Tandem Diabetes Care?

Tandem Diabetes Care (NASDAQ:TNDM) and Carlsmed (NASDAQ:CARL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Tandem Diabetes Care currently has a consensus target price of $29.34, indicating a potential upside of 80.23%. Carlsmed has a consensus target price of $19.25, indicating a potential upside of 26.40%. Given Tandem Diabetes Care's higher possible upside, equities research analysts plainly believe Tandem Diabetes Care is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.48
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Carlsmed has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	1.12	-$204.71M	-$0.93	N/A
Carlsmed	$50.51M	8.23	-$29.63M	-$1.43	N/A

Tandem Diabetes Care has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market. Comparatively, Carlsmed has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market.

Tandem Diabetes Care has a net margin of -6.08% compared to Carlsmed's net margin of -57.42%. Carlsmed's return on equity of -38.06% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%
Carlsmed	-57.42%	-38.06%	-28.96%

In the previous week, Tandem Diabetes Care and Tandem Diabetes Care both had 5 articles in the media. Tandem Diabetes Care's average media sentiment score of 1.56 beat Carlsmed's score of 0.62 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Carlsmed	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tandem Diabetes Care beats Carlsmed on 8 of the 14 factors compared between the two stocks.

Get Carlsmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CARL vs. The Competition

Export

Metric	Carlsmed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$418.82M	$5.54B	$7.20B	$15.01B
Dividend Yield	N/A	1.79%	2.57%	12.21%
P/E Ratio	-10.65	25.08	272.86	25.31
Price / Sales	8.23	72.21	701.69	107.99
Price / Cash	N/A	32.78	77.71	51.48
Price / Book	4.09	5.99	10.37	6.18
Net Income	-$29.63M	$150.13M	$3.49B	$357.96M
7 Day Performance	1.60%	-1.19%	-0.76%	-0.56%
1 Month Performance	6.35%	-3.80%	-0.39%	-3.62%
1 Year Performance	-0.46%	8.43%	18.93%	6.05%

Carlsmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CARL Carlsmed	2.7631 of 5 stars	$15.23 -0.7%	$19.25 +26.4%	+4.0%	$418.82M	$50.51M	N/A	127	News Coverage
OMCL Omnicell	4.363 of 5 stars	$34.37 -1.3%	$57.86 +68.3%	+1.1%	$1.56B	$1.25B	40.92	3,580	Positive News
KMTS Kestra Medical Technologies	1.6621 of 5 stars	$25.54 +1.6%	$28.14 +10.2%	+11.0%	$1.50B	$95.13M	N/A	300	Trending News Earnings Report Analyst Forecast Gap Down
CNMD CONMED	1.7022 of 5 stars	$48.97 -0.9%	$41.40 -15.5%	-9.5%	$1.48B	$1.37B	26.47	3,900	Positive News
ATEC Alphatec	4.1915 of 5 stars	$9.45 +1.3%	$17.40 +84.1%	-29.2%	$1.46B	$815.05M	N/A	700	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CARL) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Carlsmed (CARL) Competitors